Literature DB >> 33574799

Effect and Relationship of Seasons on the High Risk of Ovarian Hyperstimulation Syndrome After Oocyte Retrieval in Patients With Polycystic Ovary Syndrome.

Yurong Cao1,2,3, Hao Shi1,2,3, Yue Ma1,2,3, Linna Ma1,2,3, Jun Zhai1,2,3.   

Abstract

Objective: To investigate the effect of seasons on the incidence of high risk of ovarian hyperstimulation syndrome (OHSS) after in oocyte retrieval in patients with polycystic ovarian syndrome (PCOS) and to establish a nomogram to predict the risk of OHSS. Design: Single-center, retrospective study. Setting: University-affiliated reproductive medicine center. Patients: A total of 2,030 infertility patients with PCOS underwent the follicular phase long-acting long protocol IVF/ICSI in the reproductive medicine center from January 2017 to December 2019. Interventions: None. Main outcome measures: Logistic regression analysis was used to analyze the factors associated with a high risk of OHSS. We established a nomogram to predict the risk of OHSS in infertility patients with PCOS after oocyte retrieval.
Results: The incidence of patients at high risk of OHSS was significantly different from season-to-season and was especially higher in the summer and winter. Multivariate logistic analysis showed that gonadotropin dosage, number of retrieved oocytes, estradiol level, average bilateral ovarian diameter on the day human chorionic gonadotropin was administered, type of infertility, and average temperature were independent risk factors for OHSS after oocyte retrieval in PCOS patients. Based on the above independent risk factors, we constructed a prediction model for OHSS risk. To evaluate the efficiency of the prediction model, we calculated the C-index (0.849), area under the receiver operating characteristic curve (0.849), and internal validation C-index (0.846). Decision curve analysis suggested that the prediction model exhibited significant net benefits. Conclusions: The incidence of PCOS patients at high risk for OHSS after oocyte retrieval fluctuated with seasonal temperature changes, and was significantly higher in extreme climates. The prediction model had favorable predictive performance and clinical application value.
Copyright © 2021 Cao, Shi, Ma, Ma and Zhai.

Entities:  

Keywords:  nomogram; ovarian hyperstimulation syndrome; polycystic ovary syndrome; receiver operating characteristic curve; temperature change

Mesh:

Year:  2021        PMID: 33574799      PMCID: PMC7870698          DOI: 10.3389/fendo.2020.610828

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  27 in total

1.  Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles.

Authors:  Tsung-Hsien Lee; Chung-Hsien Liu; Chuin-Chia Huang; Yi-Ling Wu; Yang-Tse Shih; Hong-Nerng Ho; Yu-Shih Yang; Maw-Shang Lee
Journal:  Hum Reprod       Date:  2007-11-13       Impact factor: 6.918

2.  Optimal follicle and oocyte numbers for cryopreservation of all embryos in IVF cycles at risk of OHSS.

Authors:  Gideon R Verwoerd; Thomas Mathews; Peter R Brinsden
Journal:  Reprod Biomed Online       Date:  2008-09       Impact factor: 3.828

3.  An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.

Authors:  Negjyp Sopa; Elisabeth Clare Larsen; Helene Westring Hvidman; Anders Nyboe Andersen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2019-04-12       Impact factor: 2.435

4.  Seasonal variations and climatic factors on acute primary angle-closure admission in southern China: a 5-year hospital-based retrospective study.

Authors:  Xin Zhong; Yan Li; Chukai Huang; Tsz Kin Ng; Limei Weng; Jing Zhang; Mingzhi Zhang; Yuqiang Huang
Journal:  Acta Ophthalmol       Date:  2020-10-29       Impact factor: 3.761

5.  The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.

Authors:  Lin-Hung Wei; Chia-Hung Chou; Min-Wei Chen; Stefan Rose-John; Min-Liang Kuo; Shee-Uan Chen; Yu-Shih Yang
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

6.  Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome.

Authors:  Baris Ata; Kayhan Yakin; Cengiz Alatas; Bulent Urman
Journal:  Fertil Steril       Date:  2007-11-14       Impact factor: 7.329

Review 7.  Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.

Authors: 
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

8.  The Dual Role of PEDF in the Pathogenesis of OHSS: Negating Both Angiogenic and Inflammatory Pathways.

Authors:  Irit Miller; Dana Chuderland; Hadas Grossman; Raphael Ron-El; Ido Ben-Ami; Ruth Shalgi
Journal:  J Clin Endocrinol Metab       Date:  2016-09-28       Impact factor: 5.958

Review 9.  Daily and seasonal mitochondrial protection: Unraveling common possible mechanisms involving vitamin D and melatonin.

Authors:  Feres José Mocayar Marón; León Ferder; Russel J Reiter; Walter Manucha
Journal:  J Steroid Biochem Mol Biol       Date:  2020-01-16       Impact factor: 4.292

Review 10.  Chronic psychosocial stressors in adulthood: Studies in mice, rats and tree shrews.

Authors:  Christopher R Pryce; Eberhard Fuchs
Journal:  Neurobiol Stress       Date:  2016-10-06
View more
  2 in total

1.  Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Di Wu; Hao Shi; Yiping Yu; Ting Yu; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

2.  A Personalized Management Approach of OHSS: Development of a Multiphase Prediction Model and Smartphone-Based App.

Authors:  Mingzhu Cao; Zhi Liu; Yanshan Lin; Yiqun Luo; Sichen Li; Qing Huang; Haiying Liu; Jianqiao Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.